Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus

Endocrinology and Metabolism Clinics of North America

Volumn 47, Issue 1, 2018, Pages 117-135

  Jorsal, Anders ^a,b   Wiggers, Henrik ^a,b   McMurray, John J V ^c,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cardiac function; Cardiovascular events; Glucose lowering therapy; Glycemia; Heart failure; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BROMOCRIPTINE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; NATEGLINIDE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; VOGLIBOSE; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FRACTURE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART PROTECTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85037670718     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2017.10.007     Document Type: Review

References (95)

1. Ponikowski, P., Voors, A.A., Anker, S.D., et al. Authors/Task Force Members, Document Reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:8 (2016), 891–975.
2. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail 23:8 (2017), 628–651.
3. Jia, G., DeMarco, V.G., Sowers, J.R., Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 12:3 (2016), 144–153.
4. Schmidt, M., Jacobsen, J.B., Lash, T.L., et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ, 344, 2012, e356.
5. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:23 (1987), 1429–1435.
6. SOLVD Investigators, Yusuf, S., Pitt, B., Davis, C.E., et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:5 (1991), 293–302.
7. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:9169 (1999), 2001–2007.
8. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:10 (1999), 709–717.
9. Redfield, M.M., Jacobsen, S.J., Burnett, J.C. Jr., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:2 (2003), 194–202.
10. Nichols, G.A., Hillier, T.A., Erbey, J.R., et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24:9 (2001), 1614–1619.
11. Bertoni, A.G., Hundley, W.G., Massing, M.W., et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27:3 (2004), 699–703.
12. Sarma, S., Mentz, R.J., Kwasny, M.J., et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 15:2 (2013), 194–202.
13. Maggioni, A.P., Greene, S.J., Fonarow, G.C., et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 34:40 (2013), 3117–3127.
14. Kannel, W.B., McGee, D.L., Diabetes and cardiovascular disease. The Framingham study. JAMA 241:19 (1979), 2035–2038.
15. Nichols, G.A., Gullion, C.M., Koro, C.E., et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:8 (2004), 1879–1884.
16. Juhaeri, J., Gao, S., Dai, W.S., Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 18:6 (2009), 497–503.
17. Berl, T., Hunsicker, L.G., Lewis, J.B., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:7 (2003), 542–549.
18. Carr, A.A., Kowey, P.R., Devereux, R.B., et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96:11 (2005), 1530–1536.
19. De Groote, P., Lamblin, N., Mouquet, F., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25:8 (2004), 656–662.
20. Cubbon, R.M., Adams, B., Rajwani, A., et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 10:4 (2013), 330–336.
21. Gustafsson, I., Torp-Pedersen, C., Kober, L., et al. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 34:1 (1999), 83–89.
22. Haas, S.J., Vos, T., Gilbert, R.E., et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:5 (2003), 848–853.
23. Brown, A., Reynolds, L.R., Bruemmer, D., Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7:7 (2010), 369–375.
24. Stratton, I.M., Adler, A.I., Neil, H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:7258 (2000), 405–412.
25. ACCORD Study Group, Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:17 (2010), 1575–1585.
26. ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:24 (2008), 2560–2572.
27. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:2 (2009), 129–139.
28. Hayward, R.A., Reaven, P.D., Wiitala, W.L., et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372:23 (2015), 2197–2206.
29. Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385:9982 (2015), 2107–2117.
30. Eshaghian, S., Horwich, T.B., Fonarow, G.C., An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J, 151(1), 2006, 91.
31. Look AHEAD Research Group, Wing, R.R., Bolin, P., Brancati, F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:2 (2013), 145–154.
32. Sundstrom, J., Bruze, G., Ottosson, J., et al. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 135:17 (2017), 1577–1585.
33. Miche, E., Herrmann, G., Nowak, M., et al. Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure. Clin Res Cardiol 95:Suppl 1 (2006), i117–i124.
34. O'Connor, C.M., Whellan, D.J., Lee, K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301:14 (2009), 1439–1450.
35. Banks, A.Z., Mentz, R.J., Stebbins, A., et al. Response to exercise training and outcomes in patients with heart failure and diabetes mellitus: insights from the HF-ACTION trial. J Card Fail 22:7 (2016), 485–491.
36. Kitzman, D.W., Brubaker, P., Morgan, T., et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315:1 (2016), 36–46.
37. Asakura, M., Kim, J., Asanuma, H., et al. Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?. Cardiovasc Drugs Ther, 2017 [Epub ahead of print].
38. Holman, R.R., Coleman, R.L., Chan, J.C.N., et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol, 2017, 10.1016/S2213-8587(17)30309-1.
39. Kim, J., Nakatani, S., Hashimura, K., et al. Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy. Hypertens Res 29:10 (2006), 775–782.
40. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:9131 (1998), 854–865.
41. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:15 (2008), 1577–1589.
42. Wong, A.K., Symon, R., AlZadjali, M.A., et al. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 14:11 (2012), 1303–1310.
43. Eurich, D.T., Majumdar, S.R., McAlister, F.A., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:10 (2005), 2345–2351.
44. Masoudi, F.A., Inzucchi, S.E., Wang, Y., et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:5 (2005), 583–590.
45. MacDonald, M.R., Eurich, D.T., Majumdar, S.R., et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General practice research database. Diabetes Care 33:6 (2010), 1213–1218.
46. Evans, J.M., Doney, A.S., AlZadjali, M.A., et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 106:7 (2010), 1006–1010.
47. Roussel, R., Travert, F., Pasquet, B., et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:21 (2010), 1892–1899.
48. Andersson, C., Olesen, J.B., Hansen, P.R., et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53:12 (2010), 2546–2553.
49. Aguilar, D., Chan, W., Bozkurt, B., et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 4:1 (2011), 53–58.
50. Eurich, D.T., Weir, D.L., Majumdar, S.R., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6:3 (2013), 395–402.
51. Eurich, D.T., Tsuyuki, R.T., Majumdar, S.R., et al. Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials, 10, 2009, 12.
52. Meinert, C.L., Knatterud, G.L., Prout, T.E., et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19:Suppl (1970), 789–830.
53. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 25:12 (1976), 1129–1153.
54. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:9131 (1998), 837–853.
55. Skott, P., Hother-Nielsen, O., Bruun, N.E., et al. Effects of insulin on kidney function and sodium excretion in healthy subjects. Diabetologia 32:9 (1989), 694–699.
56. ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:4 (2012), 319–328.
57. Nielsen, R., Wiggers, H., Thomsen, H.H., et al. Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Res Care, 4(1), 2016, e000202.
58. Domanski, M., Krause-Steinrauf, H., Deedwania, P., et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42:5 (2003), 914–922.
59. Smooke, S., Horwich, T.B., Fonarow, G.C., Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:1 (2005), 168–174.
60. Pocock, S.J., Wang, D., Pfeffer, M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27:1 (2006), 65–75.
61. Guan, Y., Hao, C., Cha, D.R., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:8 (2005), 861–866.
62. Endo, Y., Suzuki, M., Yamada, H., et al. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARgamma-dependent nongenomic signaling. Cell Metab 13:5 (2011), 550–561.
63. Emoto, M., Fukuda, N., Nakamori, Y., et al. Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione. Diabetologia 49:9 (2006), 2217–2218.
64. Lago, R.M., Singh, P.P., Nesto, R.W., Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370:9593 (2007), 1129–1136.
65. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:9681 (2009), 2125–2135.
66. Komajda, M., McMurray, J.J., Beck-Nielsen, H., et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31:7 (2010), 824–831.
67. Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:9493 (2005), 1279–1289.
68. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374:14 (2016), 1321–1331.
69. Vaccaro, O., Masulli, M., Nicolucci, A., et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol, 2017, 10.1016/S2213-8587(17)30317-0.
70. Dargie, H.J., Hildebrandt, P.R., Riegger, G.A., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49:16 (2007), 1696–1704.
71. Giles, T.D., Elkayam, U., Bhattacharya, M., et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 16:3 (2010), 111–117.
72. Nesto, R.W., Bell, D., Bonow, R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108:23 (2003), 2941–2948.
73. Drucker, D.J., The biology of incretin hormones. Cell Metab 3:3 (2006), 153–165.
74. Madsbad, S., Schmitz, O., Ranstam, J., et al., NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27:6 (2004), 1335–1342.
75. Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:6 (2014), 992–1019.
76. Hocher, B., Reichetzeder, C., Alter, M.L., Renal and cardiac effects of DPP4 inhibitors–from preclinical development to clinical research. Kidney Blood Press Res 36:1 (2012), 65–84.
77. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:14 (2013), 1317–1326.
78. Scirica, B.M., Braunwald, E., Raz, I., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:18 (2014), 1579–1588.
79. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:14 (2013), 1327–1335.
80. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:3 (2015), 232–242.
81. McMurray, J.J., Ponikowksi, P., Bolli, G.B., et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure. a randomized placebo-controlled trial. JACC Heart Fail, 2017, 10.1016/j.jchf.2017.08.004.
82. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:23 (2015), 2247–2257.
83. Marso, S.P., Poulter, N.R., Nissen, S.E., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 166:5 (2013), 823–830.e5.
84. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:4 (2016), 311–322.
85. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:19 (2016), 1834–1844.
86. Holman, R.R., Bethel, M.A., Mentz, R.J., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:13 (2017), 1228–1239.
87. Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316:5 (2016), 500–508.
88. Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE): a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19:1 (2017), 69–77.
89. Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37:42 (2016), 3192–3200.
90. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.
91. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:7 (2017), 644–657.
92. Califf, R.M., Boolell, M., Haffner, S.M., et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 156:4 (2008), 623–632.
93. NAVIGATOR Study Group, Holman, R.R., Haffner, S.M., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:16 (2010), 1463–1476.
94. Gaziano, J.M., Cincotta, A.H., O'Connor, C.M., et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33:7 (2010), 1503–1508.
95. Gaziano, J.M., Cincotta, A.H., Vinik, A., et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc, 1(5), 2012, e002279.